477 related articles for article (PubMed ID: 9053841)
1. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
[TBL] [Abstract][Full Text] [Related]
2. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site.
Ladanyi M; Cavalchire G
Genes Chromosomes Cancer; 1996 Mar; 15(3):173-7. PubMed ID: 8721682
[TBL] [Abstract][Full Text] [Related]
3. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
4. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).
Morris SW; Naeve C; Mathew P; James PL; Kirstein MN; Cui X; Witte DP
Oncogene; 1997 May; 14(18):2175-88. PubMed ID: 9174053
[TBL] [Abstract][Full Text] [Related]
5. Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.
Hernández L; Campo E
Methods Mol Med; 2005; 115():295-314. PubMed ID: 15998975
[TBL] [Abstract][Full Text] [Related]
6. cDNA cloning, molecular characterization, and chromosomal localization of NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene preferentially expressed in brain.
Tang XX; Biegel JA; Nycum LM; Yoshioka A; Brodeur GM; Pleasure DE; Ikegaki N
Genomics; 1995 Sep; 29(2):426-37. PubMed ID: 8666391
[TBL] [Abstract][Full Text] [Related]
7. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
8. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the expression of the ALK receptor tyrosine kinase in mice.
Vernersson E; Khoo NK; Henriksson ML; Roos G; Palmer RH; Hallberg B
Gene Expr Patterns; 2006 Jun; 6(5):448-61. PubMed ID: 16458083
[TBL] [Abstract][Full Text] [Related]
10. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
Lamant L; Gascoyne RD; Duplantier MM; Armstrong F; Raghab A; Chhanabhai M; Rajcan-Separovic E; Raghab J; Delsol G; Espinos E
Genes Chromosomes Cancer; 2003 Aug; 37(4):427-32. PubMed ID: 12800156
[TBL] [Abstract][Full Text] [Related]
11. MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia.
Xie J; Briggs JA; Morris SW; Olson MO; Kinney MC; Briggs RC
Exp Hematol; 1997 Oct; 25(11):1111-7. PubMed ID: 9328447
[TBL] [Abstract][Full Text] [Related]
12. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
[TBL] [Abstract][Full Text] [Related]
13. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.
Mason DY; Pulford KA; Bischof D; Kuefer MU; Butler LH; Lamant L; Delsol G; Morris SW
Cancer Res; 1998 Mar; 58(5):1057-62. PubMed ID: 9500471
[TBL] [Abstract][Full Text] [Related]
14. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis.
Marazziti D; Gallo A; Golini E; Matteoni R; Tocchini-Valentini GP
Genomics; 1998 Nov; 53(3):315-24. PubMed ID: 9799598
[TBL] [Abstract][Full Text] [Related]
17. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.
Pulford K; Falini B; Cordell J; Rosenwald A; Ott G; Müller-Hermelink HK; MacLennan KA; Lamant L; Carbone A; Campo E; Mason DY
Am J Pathol; 1999 Jun; 154(6):1657-63. PubMed ID: 10362790
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
19. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
20. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
